A model for optimizing adenoviral delivery in human cancer gene therapy trials

Human Gene Therapy

Volumn 18, Issue 6, 2007, Pages 562-572

  Barton, Kenneth N ^a   Freytag, Svend O ^a   Nurushev, Teamour ^a   Yoo, Sua ^a   Lu, Mei ^a   Yin, Fang Fang ^a   Li, Shidong ^a   Movsas, Benjamin ^a   Jae, Ho Kim ^a   Brown, Stephen L ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ALGORITHM; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRACHYTHERAPY; CANCER PATIENT; CANCER THERAPY; COMPUTER PROGRAM; DOG; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN TISSUE; MALE; MODEL; NONHUMAN; PROSTATE CANCER; REPORTER GENE; SOLID TUMOR; TREATMENT PLANNING; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; GENE THERAPY; GENETIC VECTORS; HUMANS; IN SITU HYBRIDIZATION; MALE; MICE; PROSTATIC NEOPLASMS; SYMPORTERS; TRANSPLANTATION, HETEROLOGOUS;

ADENOVIRIDAE;

EID: 34447126303     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.004     Document Type: Article

References (17)

1. BARTON, K.N., TYSON, D., STRICKER, H., LEW, Y.S., HEISEY, G., KOUL, S., DE LA ZERDA, A., YIN, F.F., YAN, H., NAGARAJA, T.N., RANDALL, K.A., JIN, G.K., FENSTERMACHER, J.D., JHIANG, S., KIM, J.H., FREYTAG, S.O., and BROWN, S.L. (2003). GENIS: Gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol. Ther. 8, 508-518.
2. BARTON, K.N., XIA, X., YAN, H., STRICKER, H., HEISEY, G., YIN, F.F., NAGARAJA, T.N., ZHU, G., KOLOZSVARY, A., FENSTERMACHER, J.D., LU, M., KIM, J.H., FREYTAG, S.O., and BROWN, S.L. (2004). A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors. Mol. Ther. 9, 625-631.
3. BARTON, K.N., PAIELLI, D., ZHANG, Y., KOUL, S., BROWN, S.L., LU, M., SEELY, J., KIM, J.H., and FREYTAG, S.O. (2006a). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 13, 347-356.
4. BARTON, K.N., STRICKER, H., KOLOZSVARY, A., KOHL, R., HEISEY, G., NAGARAJA, T.N., ZHU, G., LU, M., KIM, J.H., FREYTAG, S.O., and BROWN, S.L. (2006b). Polyethylene glycol (molecular weight 400 DA) vehicle improves gene expression of adenovirus mediated gene therapy. J. Urol. 175, 1921-1925.
5. BOX, G.E.P., and COX, D.R. (1964). An analysis of transformations. J. R. Stat. Soc. Ser. B 26, 211-246.
6. CHEN, Y., DEWEESE, T., DILLEY, J., ZHANG, Y., LI, Y., RAMESH, N., LEE, J., PENNATHUR-DAS, R., RADZYMINSKI, J., WYPYCH, J., BRIGNETTI, D., SCOTT, S., STEPHENS, J., KARPF, D.B., HENDERSON, D.R., and YU, D.C. (2001). CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 61, 5453-5460.
7. DEWEESE, T.L., VAN DER POEL, H., LI, S., MIKHAK, B., DREW, R., GOEMANN, M., HAMPER, U., DEJONG, R., DETORIE, N., RODRIGUEZ, R., HAULK, T., DEMARZO, A.M., PIANTADOSI, S., YU, D.C., CHEN, Y., HENDERSON, D.R., CARDUCCI, M.A., NELSON, W.G., and SIMONS, J.W. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472.
8. DILLEY, J., REDDY, S., KO, D., NGUYEN, N., ROJAS, G., WORKING, P., and YU, D.C. (2005). Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther. 12, 715-722.
9. FREYTAG, S.O., ROGULSKI, K.R., PAIELLI, D.L., GILBERT, J.D., and KIM, J.H. (1998). A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323-1333.
10. FREYTAG, S.O., PAIELLI, D., WING, M., ROGULSKI, K., BROWN, S., KOLOZSVARY, A., SEELY, J., BARTON, K., DRAGOVIC, A., and KIM, J.H. (2002a). Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int. J. Radiat. Oncol. Biol. Phys. 54, 873-885.
11. FREYTAG, S.O., KHIL, M., STRICKER, H., PEABODY, J., MENON, M., DEPERALTA-VENTURINA, M., NAFZIGER, D., PEGG, J., PAIELLI, D., BROWN, S., BARTON, K., LU, M., AGUILAR-CORDOVA, E., and KIM, J.H. (2002b). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62, 4968-4976.
12. FREYTAG, S.O., STRICKER, H., PEGG, J., PAIELLI, D., PRADHAN, D.G., PEABODY, J., DEPERALTA-VENTURINA, M., XIA, X., BROWN, S., LU, M., and KIM, J.H. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497-7506.
13. FREYTAG, S.O., MOVSAS, B., AREF, I., STRICKER, H., PEABODY, J., PEGG, J., ZHANG, Y., BARTON, K.N., BROWN, S.L., LU, M., SAVERA, A., and KIM, J.H. (2007a). Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 15, 1016-1023.
14. FREYTAG, S.O., STRICKER, H., PEABODY, J., PEGG, J., PAIELLI, D., MOVSAS, B., BARTON, K.N., BROWN, S.L., LU, M., and KIM, J.H. (2007b). Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 15, 636-642.
15. LI, S., SIMONS, J., DETORIE, N., O'ROURKE, B., HAMPER, U., and DEWEESE, T.L. (2003). Dosimetric and technical considerations for interstitial adenoviral gene therapy as applied to prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 55, 204-214.
16. ROGULSKI, K.R., WING, M.S., PAIELLI, D.L., GILBERT, J.D., KIM, J.H., and FREYTAG, S.O. (2000a). Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. 11, 67-76.
17. ROGULSKI, K.R., FREYTAG, S.O., ZHANG, K., GILBERT, J.D., PAIELLI, D.L., KIM, J.H., HEISE, C.C., and KIRN, D.H. (2000b). In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60, 1193-1196.